Merck Provides Update on the IMPROVE-IT Trial
Whitehouse Station, N.J. September 13, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, has been advised that the IMPROVE-IT Executive Committee has decided to schedule the study's second interim analysis in the first quarter of 2012, rather than as previously anticipated in late 2011. As previously disclosed, the Data Safety Monitoring Board for IMPROVE-IT plans to conduct an interim analysis for efficacy when approximately 75 percent of the pre-specified (5,250) primary clinical endpoints have occurred. The study is fully enrolled and approximately 70 percent of its pre-specified events have been reported.
About Merck
Today's Merck is a global healthcare leader working
to help the world be well. Merck is known as MSD outside the United
States and Canada. Through our prescription medicines, vaccines,
biologic therapies, and consumer care and animal health products,
we work with customers and operate in more than 140 countries to
deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships that donate and deliver our
products to the people who need them. For more information, visit
www.merck.com.
Forward-Looking Statement
This news release includes “forward-looking statements”
within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Such
statements may include, but are not limited to, statements about
the benefits of the merger between Merck and Schering-Plough,
including future financial and operating results, the combined
company’s plans, objectives, expectations and intentions and
other statements that are not historical facts. Such statements are
based upon the current beliefs and expectations of Merck’s
management and are subject to significant risks and uncertainties.
Actual results may differ from those set forth in the
forward-looking statements.
The following factors, among others, could cause actual results
to differ from those set forth in the forward-looking statements:
the possibility that the expected synergies from the merger of
Merck and Schering-Plough will not be realized, or will not be
realized within the expected time period; the impact of
pharmaceutical industry regulation and health care legislation; the
risk that the businesses will not be integrated successfully;
disruption from the merger making it more difficult to maintain
business and operational relationships; Merck’s ability to
accurately predict future market conditions; dependence on the
effectiveness of Merck’s patents and other protections for
innovative products; the risk of new and changing regulation and
health policies in the U.S. and internationally and the exposure to
litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in Merck’s 2010
Annual Report on Form 10-K and the company’s other filings
with the Securities and Exchange Commission (SEC).
Posted: September 2011
